---
title: Vacis
date: 2019-10-10T09:58:34Z
modified: 2026-08-12T09:14:17Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/vacis/"
type: portfolio
status: publish
excerpt: ""
wpid: 75435
language:
  - English
post_translations:
  - pll_5d9712ea20b0a
branchen22:
  - Cardiovascular Devices
sectors:
  - MedTech
focus_areas:
  - Cardiac Devices
  - New Materials
timestamp: 2026-08-12T09:14:17Z
tags:
  - English
  - pll_5d9712ea20b0a
  - Cardiovascular Devices
  - MedTech
  - Cardiac Devices
  - New Materials
---

## Beschreibungstext

VACIS is the leading tissue engineering company for body-own blood vessels.
The VACIS technology uses a synthetic rod which induces the formation of a new fully functional blood vessel providing novel therapeutic options for vascular surgery. Prosthetic vascular graft failure is a frequent complication in vascular surgery with substantial morbidity and health care costs. VACIS provides patients autologous graft vessels, with sustained patency and fewer complications requiring less corrective interventions.
Vascular grafts are needed in many areas of medicine. VACIS initially focuses on vascular access in patients undergoing hemodialysis. Other indications will follow after clinical validation of the technology in hemodialysis. Such other indications include peripheral arterial occlusive disease.
VACIS provides an advantage over other therapeutic options in the hemodialysis access market. Current solutions have a low patency: many arteriovascular fistulas fail to mature or no adequate vein is available; the foreign material in synthetic grafts lead to infection, stenosis, thrombosis etc. and the synthetic material does not heal after cannulation.

## Unternehmenswebsite

https://www.vacis.nl/

## Adresse

Vacis B.V.
Urmonderbaan 20B
6167 RD Geleen
The Netherlands

## Kontakt

Array